Get started
Author

Liselore Loverix

Observed names: L Loverix, L. Loverix, Loverix, Liselore
Institution: KU Leuven
Observed institutions: Oulu University Hospital, Universitair Ziekenhuis Leuven, VIB-KU Leuven Center for Cancer Biology, International Hereditary Cancer Center, Pomeranian Medical University, Hasselt University, KU Leuven
ORCID: 0000-0002-4741-6519
Observed ORCID: 0000-0002-4741-6519
OpenAlex ID: A5023315529
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification
2021 · Siel Olbrecht, Pieter Busschaert, et al. · Genome Medicine · 193
PDF
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
2022 · Eun‐Young Kang, Ashley Weir, et al. · Cancer · 51
PDF
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
2023 · Liselore Loverix, Ignace Vergote, et al. · European Journal of Cancer · 38
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
2022 · Adriaan Vanderstichele, Liselore Loverix, et al. · Gynecologic Oncology · 28
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
2022 · Adriaan Vanderstichele, Pieter Busschaert, et al. · npj Genomic Medicine · 26
PDF
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)
2022 · Liselore Loverix, Ignace Vergote, et al. · Gynecologic Oncology · 23
The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
2021 · Eva Obermayr, Angelika Reiner, et al. · Cancers · 22
PDF
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
2021 · Eun Young Kang, Joshua Millstein, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 20
Prosthetic endocarditis after transcatheter aortic valve implantation: Pooled individual patient outcome
2014 · Liselore Loverix, Tatu Juvonen, et al. · International Journal of Cardiology · 16
PDF
Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy
2020 · Liselore Loverix, Rawand Rokan Salihi, et al. · International Journal of Gynecological Cancer · 11
Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
2021 · Eva Obermayr, Elena Ioana Braicu, et al. · Cancers · 10
PDF
miR ‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients
2020 · Konstantina Panoutsopoulou, Margaritis Avgeris, et al. · International Journal of Cancer · 9
PDF
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment
2025 · Francesca Lodi, Sam Vanmassenhove, et al. · Cell Reports Medicine · 8
Successful Non-surgical Treatment of Endocarditis Caused by Staphylococcus Haemolyticus Following Transcatheter Aortic Valve Implantation (tavi)
2013 · L Loverix, P Timmermans, et al. · Acta Clinica Belgica · 7
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
2020 · Sabine Kasimir-Bauer, Joanna Roder, et al. · Cancers · 6
PDF
Single-cell profiling in ovarian germ cell and sex cord-stromal tumours
2025 · T. Laga, AS Van Rompuy, et al. · British Journal of Cancer · 5
Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
2020 · L. Loverix, A. Vanderstichele, et al. · Gynecologic Oncology · 3
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
2026 · Tibor A. Zwimpfer, Sian Fereday, et al. · Nature Communications · 2
PDF
569 The Leuven PARPi benefit test as improved approach for prediction of PARPi benefit in the PAOLA-1/ENGOTov25 trial
2024 · Liselore Loverix, Ignace Vergote, et al. · International Journal of Gynecological Cancer · 2
2022-RA-1136-ESGO A single-cell map of rare ovarian cancer
2022 · Tina Laga, Pieter Busschaert, et al. · International Journal of Gynecological Cancer · 2
PDF
817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial
2020 · A. Vanderstichele, L. Loverix, et al. · Annals of Oncology · 1
PDF
Additional telerehabilitation contributes to a sustained improvement in physical fitness in coronary artery disease patients, who have completed phase 2 of cardiac rehabilitation
2013 · I. Frederix, N. Van Driessche, et al. · European Heart Journal · 1
Association between diffusion-weighted MRI-derived radiomics textures and outcome in patients with advanced high-grade ovarian cancer: an exploratory study.
2026 · Liselore Loverix, Vincent Vandecaveye, et al. · International Journal of Gynecological Cancer
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
2025 · Dale Garsed, Tibor Zwimpfer, et al. · Research Square
PDF
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA -deficient tubo-ovarian high-grade serous carcinoma
2025 · Tibor A. Zwimpfer, Sian Fereday, et al. · medRxiv
PDF
Works count: 49
Citation count: 484
H-index: 10
I10-index: 11
Year
Topic
Type